Imunon, Inc. (NASDAQ:IMNN) Short Interest Update

Imunon, Inc. (NASDAQ:IMNN) was the recipient of a large increase in short interest in December. As of December 31st, there was short interest totalling 970,200 shares, an increase of 10.8% from the December 15th total of 876,000 shares. Based on an average trading volume of 267,600 shares, the short-interest ratio is presently 3.6 days. Currently, 7.0% of the company’s stock are short sold.

Imunon Trading Up 1.7 %

Shares of IMNN stock traded up $0.02 during trading hours on Friday, reaching $0.91. 82,573 shares of the company’s stock were exchanged, compared to its average volume of 419,037. Imunon has a 1 year low of $0.48 and a 1 year high of $3.65. The stock has a market cap of $13.24 million, a PE ratio of -0.48 and a beta of 2.04. The stock’s fifty day moving average price is $0.85 and its two-hundred day moving average price is $1.04.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Imunon in a research report on Thursday, December 19th. D. Boral Capital restated a “buy” rating and issued a $29.00 target price on shares of Imunon in a research note on Thursday, December 19th. Finally, EF Hutton Acquisition Co. I raised Imunon to a “strong-buy” rating in a research report on Monday, September 23rd.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.